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Abstract
Introduction: The early application of fibrinogen could potentially reverse haemodilution-induced coagulopathy, 
although the impact of varying concentrations of fibrinogen to reverse dilutional coagulopathy has not been studied 
in vivo. We postulated that fibrinogen concentration is correlated with blood loss in a pig model of coagulopathy with 
blunt liver injury.
Methods: Coagulopathy was induced in 18 anaesthetized pigs (32 ± 1.6 kg body weight) by replacing 80% of blood 
volume with hydroxyethylstarch 130/0.4 and Ringer's lactated solution, and re-transfusion of erythrocytes. Animals 
were randomly assigned to receive either 70 mg kg-1 (F-70) or 200 mg kg-1 (F-200) fibrinogen or placebo before 
inducing blunt liver injury using a force of 225 ± 26 Newton. Haemodynamics, coagulation parameters and blood loss 
were monitored for 2 hours. After death, histological examination of internal organs was performed to assess the 
presence of emboli and the equality of liver injury.
Results: Plasma dilution caused severe coagulopathy. Measured by thromboelastography fibrinogen restored 
coagulation dose-dependently. Total blood loss was significantly lower and survival better in both fibrinogen groups as 
compared to controls (P < 0.05). Between the F-70 (1317 ± 113 ml) and the F-200 group (1155 ± 232 ml) no significant 
difference in total blood loss could be observed, despite improved coagulation parameters in the F-200 group (P < 
0.05). Microscopy revealed even injury pattern and no (micro) thrombi for either group.
Conclusions: Restoring fibrinogen with 70 or 200 mg kg-1 after severe dilutional coagulopathy safely improved 
coagulation and attenuated blood loss after experimental blunt liver trauma. The higher dosage of fibrinogen was not 
associated with a further reduction in blood loss.
Introduction
Traumatised and surgical patients with massive haemor-
rhage are predisposed to develop coagulopathy, as a
result of multiple mechanisms including acidosis, hypo-
thermia, anaemia, hyperfibrinolysis and hypotension-
induced inflammation, as well as consumption and dilu-
tion of coagulation factors [1]. Dilutional coagulopathy
may occur after massive blood loss, as crystalloid and col-
loid solutions are infused for fluid resuscitation. The
degree of coagulopathy depends on the type and volume
of the fluids infused [2]. Resuscitation with colloid
plasma expanders may lead to a functional fibrinogen
deficiency by abnormal fibrin polymerisation, which can
be reversed by exogenous fibrinogen [3]. Furthermore,
fibrinogen concentrations of less than 100 mg dL-1 may
occur before other coagulation factors are diluted [4].
The early decrease of fibrinogen levels has led to the
hypothesis that fibrinogen is a key factor for reversing
haemodilution induced coagulopathy. Fresh frozen
plasma (FFP), cryoprecipitate and fibrinogen may be sub-
stituted to restore low concentrations of fibrinogen. FFP
contains all coagulation factors and is recommended
according to international guidelines to be used either in
massive bleeding or if a prolongation of prothrombin
time (PT) activated thromboplastin time of more than 1.5
times is accompanied by signs of microvascular bleeding
[5]. However, to restore coagulation with FFP and
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Page 2 of 9increase low levels of fibrinogen efficiently, large volumes
of FFP are needed. Other drawbacks of FFP transfusion
include immunological reactions such as transfusion-
related lung injury, anaphylaxis and haemolysis in cases
of ABO incompatibility [6]. Alternatively, cryoprecipitate
might be used to raise critical levels of fibrinogen, con-
taining factor VIII, fibrinogen, fibronectin, von Wille-
brand factor and factor XIII [7]. A dose of around 10
single bags of cryoprecipitate derived from units of whole
blood typically raises the plasma fibrinogen level by up to
60 to 100 mg dL-1. However, due to the risk of blood-
borne pathogen transmission, the use of cryoprecipitate
for this indication is discussed critically. In respect to FFP
and cryoprecipitate pasteurised fibrinogen is virus inacti-
vated. In a pioneering study Fries and colleagues could
demonstrate that the early application of 250 mg kg-1
fibrinogen reversed haemodilution-induced coagulopa-
thy and reduced blood loss in a porcine model of liver
injury [8]. Subsequent studies confirmed these findings
and also showed a dose-dependent effect of fibrinogen
substitution on thromboelastometry variables in vitro [9-
11]. However, as in vitro studies are performed under low
shear conditions, the effects of the interaction with vas-
cular endothelium were not investigated and relevant
clinical outcomes in relation to increasing doses of fibrin-
ogen, such as blood loss and survival rate, remained
unknown [12,13]. Therefore this study investigated a pos-
sible dose-dependent effect of fibrinogen to reverse hae-
modilution in vivo in a model of blunt liver injury.
Primary endpoints of this study included blood loss and
survival time, secondary endpoints were improvement in
coagulation tests including thromboelastometry and the
evaluation of adverse events.
Materials and methods
Ethics and anaesthesia
All experiments were performed in accordance with the
German legislation governing animal studies following
The Principles of Laboratory Animal Care [14]. Official
permission for this study was granted from the govern-
mental animal care and use office (Landesamt für Natur,
Umwelt und Verbraucherschutz Nordrhein-Westfalen,
Recklinghausen, Germany).
Before surgery, pigs were housed in ventilated rooms
and allowed to acclimatise to their surroundings for a
minimum of five days. Animals were fasted overnight
before surgical procedure, with water allowed ad libitum.
Eighteen German male land-race pigs, weighing (mean
± standard deviation (SD)) 32 ± 1.6 kg received an intra-
muscular injection of 4 mg kg-1 azaperone (Stresnil™,
Janssen, Neuss, Germany) as pre-medication. Anaesthe-
sia was induced by an intravenous injection of 3 mg kg-1
propofol (Disoprivan®, Astra Zeneca, Wedel, Germany)
followed by orotracheal intubation. The animals were
ventilated with 20 to 26 breaths min-1 and a tidal volume
of 10 mL kg-1 to keep the end-tidal partial pressure of car-
bon dioxide (pCO2) between 36 and 42 mmHg. The
inspiratory oxygen fraction was 1.0 during haemodilution
and reduced to 0.4 afterwards. Anaesthesia was main-
tained with isoflurane at end-tidal concentrations of 1%
to 1.2% and continuous infusion of fentanyl at 3 μg kg-1 h-
1. Ringer's lactated solution (RL) was infused at 4 mL kg-
1h-1 at first and increased to 8 mL kg-1h-1after laparotomy
until infliction of trauma. Body temperature was main-
tained over the entire experiment (36.5 to 37.0°C) with a
warming blanket.
Monitoring included electrocardiography, tail pulse
oximetry, temperature and arterial and central venous
pressure by femorally introduced catheters connected to
a standard anaesthesia monitor (AS/3, Datex Ohmeda,
Helsinki, Finland).
Surgical preparation and haemodilution
Two 8.5 Fr catheters were surgically implanted in the
right and left jugular veins for volume substitution and
insertion of a pulmonary artery catheter. A splenectomy
was performed under neuromuscular blockage with pan-
curonium (0.2 mg kg-1 intravenous). To compensate for
blood loss associated with the splenectomy, a bolus of
warmed RL three times the weight of the spleen was
administered. To achieve comparable low concentrations
of fibrinogen, intravascular volume was diluted by replac-
ing approximately 80% of the estimated blood volume
[15] by hydroxyethylstarch 130/0.4 (Voluven®, Fresenius,
Bad Homburg, Germany) with a maximum dose of 50 ml
kg-1 and RL in a ratio of 1:1.2 to 1.5. The collected blood
was processed (Cell Saver 5®, Haemonetics, Munich, Ger-
many) and the red cells were re-transfused before trauma
infliction to avoid early death from severe anaemia.
Fibrinogen substitution and liver injury
Six animals each were randomised to receive normal
saline solution (controls), 70 mg kg-1 fibrinogen (group F-
70; fibrinogen: Haemocompletan®, CSL Behring, Mar-
burg, Germany), or 200 mg kg-1 (group F-200) fibrinogen.
Subsequently, a grade III blunt liver injury [16] was
inflicted as described before using a custom-made instru-
ment [17]. Briefly, the liver was gently retracted to allow
adequate exposure. The base of the plate was positioned
beneath the right middle lobe. The injury was induced by
one-time clamping of the instrument through the paren-
chyma with a force of 225 ± 26 Newton (N). The force of
injury was analysed in real-time and the signal was dis-
played in a visual programming environment (LabView
8.8, National Instruments, Austin, TX, USA) after ampli-
fying (VG140, ATR Industrie-Elektronik, Krefeld, Ger-
many) and digitizing the force signal (NI USB-6009,
National Instruments, Austin, TX, USA). The time of reg-
Grottke et al. Critical Care 2010, 14:R62
http://ccforum.com/content/14/2/R62
Page 3 of 9istration was set to 500 msec. In all cases the injury was
inflicted by the same investigator (OG), being also
blinded to the experimental group.
After liver injury, the abdomen was closed with staples
and further manipulations were avoided. Five minutes
after injury all animals received 4 mL kg -1 min-1 of RL
given over eight minute. Afterwards, the rate was set to
25 mL kg-1 h-1 until the end of the experiment. The obser-
vation period ended at 120 minutes after injury. Pulseless
electrical activity, a mean arterial pressure of less than 10
mmHg and an end-tidal PCO2 of less than 10 mmHg
were defined as death. Animals surviving for more than
two hours were killed with fentanyl, propofol and potas-
sium chloride. Immediately after death, the abdomen was
reopened, the vena cava was clamped cranial to the liver
and the intraperitoneal blood was collected to determine
the total blood loss post-injury. After that, internal organs
(lungs, heart, liver and kidneys) were removed and pre-
pared for histological examination.
Blood sampling and analytical methods
Blood was collected and arterial blood gas analysis were
performed 10 minutes after splenectomy ('baseline'), at
the end of haemodilution ('haemodilution'), after fibrino-
gen substitution ('fibrinogen') and 120 minutes after liver
injury ('trauma') or immediately following death, which-
ever occurred first. Haemoglobin concentration, pH
value, partial pressure of oxygen (pO2) and carbon diox-
ide (pCO2) were measured with a blood gas analyser
(ABL500, Radiometer, Copenhagen, Denmark). Pro-
thrombin time (PT), activated partial thromboplastin
time (aPTT) and fibrinogen concentrations were deter-
mined by standard laboratory methods using the appro-
priate tests from Dade Behring (Marburg, Germany) on a
coagulometer (KC4, Baxter, Newbury, UK). Thrombin-
antithrombin (TAT) complexes were quantified by ELISA
(TAT, Dade Behring, Germany). A coagulation analyser
(ROTEM®, Pentapharm, Munich, Germany) was used for
thrombelastometry with the EXTEM® assay according to
the manufacturer's instructions. The following parame-
ters were obtained: clot formation time (CFT in seconds:
reflects the coagulation time until 20 mm of amplitude
are reached), maximum clot firmness (MCF in mm:
reflects the strength of a resulting clot) and the α-angle
(in degree: shows the rate of fibrin polymerisation).
Pathological examination
All investigated internal organs, such as the lungs, the
heart, liver and the kidneys, were removed after death
and directly fixed in 10% buffered formalin. Injured parts
of the liver were cut into 3 mm thick slices. Only areas of
maximum depth of injury and most severe vessel rupture
were chosen for further histological examination. In addi-
tion representative tissue sections of all four organs were
processed to explore for thrombotic events. All samples
were embedded in paraffin and stained by H&E and a
standard Elastica-van Gieson protocol for histological
examination under light microscopy (Eclipse 50i, Nikon,
Duesseldorf, Germany). Secondary, suspect sections of
lung and liver tissues were immunostained for fibrinogen
and von Willebrand factor. A polyclonal rabbit antihu-
man fibrinogen antibody (DAKO A0080, polyclonal rab-
bit, DAKO, Glostrup, Denmark) and polyclonal rabbit
von Willebrand factor VIII antibody (DAKO, A0082,
polyclonal rabbit) were used at a concentration of 1:100.
For staining, the ABC Vectastain universal kit (Vector
Laboratories, Burlingame, CA, USA) and haematoxylin as
counterstain was used. A blinded pathologist subse-
quently assessed the degree of injury in the liver and of
fibrin deposition in vessels and microthrombi formation
in all organs.
Statistical analysis
Data are presented as mean ± SD (SPSS V16, Chicago, IL,
USA). Normal distribution of parameters was shown on
the interpretation of Q-Q plots and histograms. Differ-
ences between groups were analysed with a one-way
analysis of variance (ANOVA) with Scheffe's post hoc test
and Games Howell for multiple comparisons, respec-
tively. A repeated measures ANOVA was applied to anal-
yse the influence of dilution and treatment substitution
over time using Scheffe's post hoc and Games Howell
tests.
Non-parametric distributed parameters of throm-
boelastometry were analysed using Kruskal-Wallis H-test
and Bonferroni-Dunn tests for multiple comparisons.
Data are presented in box plots. Data on survival were
analysed by the log-rank test. Statistical tests were per-
formed two-tailed and the level of significance was
defined as P < 0.05.
Results
Baseline measurements and coagulation parameters after 
haemodilution
Baseline parameters were comparable between groups
(Tables 1 and 2). The dilution caused a significant coagul-
opathy and a drop in platelets. PT increased from 9.3 ±
0.7 seconds to 19 ± 2 seconds (pooled data) whereas
fibrinogen concentrations decreased from 301 ± 36 mg
dL-1 to 54 ± 7 mg dL-1 (P < 0.001; Figure 1). Coagulopathy
was adequately detected by significant findings in throm-
boelastometry (P < 0.001; Figure 2). No clinical signs of
coagulopathy, such as oozing from insertion sites or
mucosal bleeding, were observed in any group.
Coagulation parameters after fibrinogen substitution and 
after injury
Fibrinogen substitution significantly increased the con-
centrations of fibrinogen in the intervention groups (F-
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PT decreased equally in both intervention groups (Figure
1), the decrease in CFT and the increases in MCF and α-
angle were dose dependent (Figure 2).
After haemodilution and liver injury fibrinogen con-
centrations decreased in all groups over time. However,
in the F-200 group, fibrinogen concentration was signifi-
cantly higher (131 ± 26 mg dL-1) and PT lower (11 ± 1
seconds) than in F-70 group (fibrinogen: 67 ± 11 mg dL-1,
PT 17 ± 2 seconds). Corresponding results were obtained
by thromboelastometry (Figure 2), with controls showing
consistently lowest (MCF, α-angle), respectively highest
values (CFT).
The aPTT was significantly prolonged after dilution,
without significant differences between groups. Similarly,
TAT complexes increased in all groups without signifi-
cant differences between groups (Table 1). Concentra-
tions of D-Dimer were below 500 μg l-1 at all times (data
not shown).
Haemodynamics and blood loss
No differences in haemodynamics were observed
between groups until liver injury (Table 2). Following
liver injury all animals developed haemorrhagic shock.
Blood loss after liver injury was highest in the control
group (1803 ± 248 ml; P < 0.05), followed by the F-70
(1317 ± 113 ml) and F-200 (1155 ± 232 ml) groups. The
difference in blood loss between the intervention groups
was not significant (P = 0.205). Mean arterial pressure
and cardiac output were significantly lower in controls
than in the intervention groups.
All animals in the control group died before the end of
the observation period, with a survival time of 59 ± 12
minutes (Figure 3). All animals in the F-200 group sur-
vived, whereas two out of six animals (33%) of the F-70
group died before the end of the observation time (P =
0.138).
Histopathological analysis
Macroscopical and histological evaluation by immunos-
taining with von Willebrand factor of injured liver sec-
tions revealed an equal tissue damage as well as
comparable laceration of venous vessels of a maximum of
3 to 4 mm. No evidence for thrombus formation or
microthrombi was found in the H&E and fibrinogen stain
of kidney, heart or lung tissues.
Discussion
In this in vivo study we could demonstrate a dose-depen-
dent effect of fibrinogen to reverse haemodilution-
induced coagulopathy. Increasing concentrations of
fibrinogen resulted in a further improvement of clot for-
mation and clot firmness. Blood loss after liver injury was
significantly lower in the fibrinogen groups as compared
Table 1: Laboratory parameters (mean ± standard deviation). Parameters included in the table are haemoglobin, platelet 
count (PLT), prothrombin time (PT), activated partial thromboplastin time (aPTT) and thrombin-AT complex (TAT) at 
baseline, after haemodilution, after fibrinogen substitution (fibrinogen) at the end of the observation period (trauma)
Baseline Haemodilution Fibrinogen Trauma
Haemoglobin (g L-1)
Control 8.2 ± 0.5 7.5 ± 0.6 7.8 ± 0.4 3.7 ± 0.4
F-70 8.1 ± 0.4 7.7 ± 0.4 7.9 ± 0.6 4.1 ± 0.3
F-200 8.0 ± 0.2 8.0 ± 0.6 8.0 ± 0.5 4.5 ± 1.7
PLT (103 μL-1)
Control 268 ± 35 85 ± 8 84 ± 11 46 ± 4
F-70 263 ± 44 87 ± 10 87 ± 13 54 ± 14
F-200 294 ± 41 94 ± 11 95 ± 12 71 ± 10*
aPTT (s)
Control 12 ± 1 22 ± 5 22 ± 5 27 ± 6
F-70 11 ± 2 24 ± 6 22 ± 5 28 ± 3
F-200 11 ± 1 23 ± 2 20 ± 2 21 ± 5
TAT (μg L-1)
Control 10.4 ± 3.2 11.3 ± 3.5 10.4 ± 3.0 17.4 ± 6.7
F-70 8.0 ± 3.0 8.1 ± 1.6 9.1 ± 1.5 12.9 ± 5.5
F-200 10.2 ± 2.8 8.5 ± 5.7 8.4 ± 2.9 12.3 ± 2.0
*P < 0.005 F-200 vs. control.
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stituting 70 or 200 mg kg-1 fibrinogen in regards to blood
loss or survival.
After haemodilution, coagulation was severely
impaired as shown by prolonged PT, clot formation and
an overall reduction in clot firmness. To meet a plasma
fibrinogen concentration below the threshold of interna-
tional recommendations (> 80 to 100 mg dL-1) [5], the
degree of haemodilution was set to achieve a fibrinogen
concentration of approximately 50 mg dL-1. Although it is
well known that colloids may interfere with concentra-
tions of fibrinogen determined by the Clauss method
[18], the prolongation of clot formation and decreased
clot strength confirmed the haemodilution induced coag-
ulopathy in our study.
In concordance with several in vitro studies we could
show that increasing concentrations of fibrinogen dose
dependently improved clot formation (lower CFT and
higher α-angle) and clot strength (increase of MCF) using
the EXTEM® assay [9-11]. Although the FIBTEM® assay
specifically attributes the impact of fibrinogen/fibrin on
clot strength by inhibiting platelets through cytochalasin-
D [19], the FIBTEM® assay cannot be reliable used with
porcine blood [20]. The observed improvement on clot
strength after fibrinogen substitution is most likely
explained by its binding to GIIb/IIIa receptors, as the
platelet count did not significantly vary after haemodilu-
tion and fibrinogen substitution. The abundant number
of approximately 40,000 to 50,000 GIIb/IIIa receptors per
activated platelet allows binding of large amounts of
fibrinogen [21]. This theory is supported by a possible
compensating role of fibrinogen with the presence of
thrombocytopenia [22,23]. However, even at very high
doses of exogenous fibrinogen, clot strength did not
reach baseline values, probably because of reduced levels
of other coagulation factors such as FXIII [24-26]. In con-
trast, prolonged PTs were reversed after fibrinogen provi-
sion, but this effect was not dose dependent. As the PT
only reflects 5% of the whole coagulation process the sub-
stitution of 70 mg kg-1 of fibrinogen already normalised
Table 2: Haemodynamic parameters (mean ± standard deviation). Parameters included in the table are heart rate (HR), 
mean arterial pressure (MAP), central venous pressure (CVP), mean pulmonary pressure (MPAP) and cardiac output (CO) at 
baseline (after splenectomy), after fibrinogen substitution (fibrinogen), haemodilution, five minutes after trauma and at 
the end of the observation period (trauma)
Baseline Haemodilution Fibrinogen 5 min after 
Trauma
Trauma
HR (beats min-1)
Control 83 ± 15 99 ± 11 99 ± 10 115 ± 12 155 ± 22
F-70 86 ± 12 92 ± 13 84 ± 11 110 ± 10 146 ± 15
F-200 87 ± 13 81 ± 18 82 ± 12 127 ± 14 175 ± 13
MAP (mmHg)
Control 79 ± 10 78 ± 6 75 ± 5 41 ± 4 13 ± 1
F-70 75 ± 9 75 ± 8 76 ± 6 39 ± 3 29 ± 7*
F-200 83 ± 11 77 ± 5 81 ± 5 45 ± 5 36 ± 4*
CVP (mmHg)
Control 8 ± 2 7 ± 2 7 ± 2 4 ± 1 1 ± 1
F-70 8 ± 1 8 ± 2 8 ± 1 5 ± 1 4 ± 0.5*
F-200 9 ± 2 8 ± 3 8 ± 1 5 ± 2 6 ± 1*
MPAP (mmHg)
Control 20 ± 1 20 ± 2 19 ± 3 14 ± 1 7 ± 2
F-70 18 ± 2 20 ± 3 20 ± 3 13 ± 2 9 ± 1
F-200 17 ± 2 18 ± 2 21 ± 3 12 ± 1 12 ± 2*
CO (L min-1)
Control 4.4 ± 0.5 4.0 ± 0.7 3.7 ± 0.7 2.5 ± 0.2 1.2 ± 0.5
F-70 3.7 ± 0.7 3.4 ± 0.4 3.4 ± 0.5 2.6 ± 0.3 2.3 ± 0.4*
F-200 4.5 ± 0.8 3.6 ± 0.9 3.6 ± 0.6 2.2 ± 0.2 2.5 ± 0.5*
*P < 0.005 vs. control.
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boelastometry variables [27]. Our observation confirms
that the sensitivity of PT is insufficient to guide haemo-
static therapy in haemodilution-induced coagulopathy
[28]. A recommendation by the Society of Thoracic Sur-
geons therefore suggests guiding haemostatic therapy by
point-of-care testing rather than by plasma-based coagu-
lation assays [29].
Following trauma, haemodilution and shock decreased
both the clot formation and clot strength in all animals.
This effect is due to the loss, consumption and dilution of
coagulation factors. However, at the end of the observa-
tion period clot strength and fibrinogen concentration
were still higher in the F-200 group as compared with the
F-70 group, but not associated with a further reduction in
blood loss. Thus the endogenous potential of procoagu-
lant activators was sufficient to activate fibrinogen and to
terminate bleeding. The comparable blood loss between
the F-70 and F-200 group and the similar decrease of the
mean concentration of fibrinogen indicates that the limit-
ing factor determining the time to haemostasis was rather
restricted by the concentration of fibrinogen than its acti-
vation. Although thrombin generation and clot formation
have been shown to be decreased at a plasma dilution of
more than 40% [30], the residual thrombin is usually suf-
ficient to cleave fibrinogen. However, trauma-induced
blood loss and haemodilution further reduced the rate of
thrombin generation that is crucial to achieve sufficient
haemostasis. Due to the short half-life time of FXa and
thrombin [31] clinical situations with dilutional coagul-
opathy and active bleeding might also require the addi-
tional substitution of procoagulant factors [32].
Although some recent studies indicate a potential pro-
tective effect of higher levels of fibrinogen to reduce
blood loss [33-36], fibrinogen is rarely used as monother-
apy but as an adjunct in clinical situations with life-
threatening bleeding. Thus the substitution of fibrinogen
may be a reasonable approach to reduce the use of allo-
genic blood products, but the efficacy of fibrinogen sub-
stitution may also be enhanced by the concomitant
application of other coagulation factors.
There is some concern that substitution of fibrinogen
may enhance the risk for thromboembolic events. This
risk may be aggravated by the concomitant application of
other haemostatics, such as antifibrinolytics. Although
some studies indicate an association between chronic ele-
vation of fibrinogen and an increased risk for cardiovas-
cular events [37], a systematic review about the safety of
fibrinogen substitution in a situation of deficit showed a
low thrombogeneity [38]. Our results are consistent with
these studies, as we could not detect (micro) vascular
thrombosis or hypercoagulability after fibrinogen substi-
tution.
Some limitations do apply. Despite the application of
up to 200 mg kg-1 fibrinogen, thromboelastometry vari-
ables were not restored to baseline values. The provision
of other coagulation factors, such as FXIII might have
shown different results. The experimental setup required
inducing the haemodilution and fibrinogen application
before the infliction of trauma. It does not exactly mirror
a clinical situation, where coagulopathy occurs after
trauma. Although we mimicked a blunt liver injury, we
allowed free bleeding after the injury, which is somewhat
similar to a clinical situation with penetrating trauma.
Figure 1 Prothrombin time and fibrinogen concentrations at baseline, after haemodilution, fibrinogen substitution (fibrinogen) and trau-
ma. Data presented as mean ± standard deviation.
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Page 7 of 9Further, the observation time of this study was limited to
only two hours, which prevented the study of further
treatment effects or possible physiological compensation
mechanisms. However, all of the control animals had died
within this observation period, which demonstrates a
clear treatment effect. In addition, the induction of injury
was performed in anaesthetised healthy pigs. Thus, the
physiological response to such things as pain and inflam-
mation may have additional effects on haemostasis,
which are not reflected in our model.
Finally, there is a great debate about the ideal resuscita-
tion fluid, which has been recently addressed in a
Cochrane systematic review [39]. It would be way beyond
the scope of this study to discuss the implications of the
fluids needed to maintain haemodynamic stability in our
pig model of severe dilutional coagulopathy. Both crystal-
loid and colloid solutions have manifold influence on the
coagulation system, inflammatory responses and organ
function. Our model of a combination of hydroxyethyl-
starch and crystalloid represents the current concept at
our institution, and probably of many other centres, for
resuscitation of haemorrhagic shock, until the optimum
resuscitation strategy has been identified.
Conclusions
In summary, dilutional coagulopathy could be reversed
by the early administration of exogenous fibrinogen in
the absence of severe anaemia. Higher doses of fibrino-
gen correlated with improved parameters of throm-
boelastometry and may be a reasonable approach to
reduce the use of FFP, platelet concentrate and red blood
cells as these allogenic blood products are associated with
various adverse outcomes. However, the results of our
study also show that substituting fibrinogen concentra-
tion to values of more than 150 mg dL-1 had no additional
effect on clinical relevant endpoints in this specific ani-
Figure 2 Thromboelastometry parameters. (a) Clot formation time, 
(b) Maximum clot firmness and (c) α-angle at various time points in-
cluding baseline, after haemodilution, fibrinogen substitution (fibrino-
gen) and trauma. Results are shown as box plots (minimum, first 
quartile, median, third quartile, maximum). *P < 0.05 vs. control; †P < 
0.05 vs. F-70.
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Page 8 of 9mal model, if no other coagulation factors or thrombo-
cytes were transfused. Thus, future clinical studies should
address the question of optimum level of fibrinogen in
combination with the replacement of other clotting fac-
tors, timing of fibrinogen substitution and patient selec-
tion.
Key messages
• We could demonstrate that restoring fibrinogen
with 70 or 200 mg kg-1 after severe dilutional coagul-
opathy dose dependently improved coagulation
parameters as shown by thromboelastometry vari-
ables.
• Although blood loss after liver injury was signifi-
cantly lower in the fibrinogen groups as compared
with controls, there was no difference between substi-
tuting 70 or 200 mg kg-1 fibrinogen in regard to blood
loss or survival. Therefore substituting fibrinogen
concentration to values above 150 mg dL-1 had no
additional effect on clinical relevant endpoints in this
specific animal model.
• As no (micro) vascular thrombosis or hypercoagula-
bility was observed, the early application of fibrinogen
might be a safe approach to restore critical concentra-
tions of fibrinogen and may reduce the need for the
transfusion of allogenic blood products.
Abbreviations
ANOVA: analysis of variance; aPTT: activated partial thromboplastin time; CFT:
clot formation time; ELISA: enzyme-linked immunosorbent assay; FFP: fresh
frozen plasma; H&E: haematoxylin and eosin; MCF: maximum clot firmness;
pCO2: partial pressure of carbon dioxide; pO2: partial pressure of oxygen; PT:
prothrombin time; RL: Ringer's lactated solution; SD: standard deviation; TAT:
thrombin-antithrombin.
Competing interests
RR has received honoraria for lectures and consultancy from CSL Behring, Ger-
many. Fibrinogen (Haemocompletan®) was provided by CSL Behring, Marburg,
Germany for the current study, but there was not financial support. The
authors declare that they have no other competing interests.
Authors' contributions
OG conceived and conducted the experimental laboratory work, performed
the statistical analysis and drafted the manuscript. RR participated in the study
design and coordination and helped to draft the manuscript. TB, MC, and RT
helped to perform the study and draft the manuscript. DH draft the manu-
script. All authors read and approved the final manuscript.
Acknowledgements
The authors thank Thaddäus Stopinski, Dr. Kira Scherer (Institute of Laboratory 
Animal Science), Daniela Smeets and Eduardo Lee (Institute of Pathology) for 
their excellent support.
Author Details
1Department of Anaesthesiology, RWTH Aachen University Hospital 
Pauwelsstrasse 30, D-52074 Aachen, Germany, 2Institute for Laboratory Animal 
Science, RWTH Aachen University Hospital, Pauwelsstrasse 30, D-52074 
Aachen, Germany, 3Department of Pathology, RWTH Aachen University 
Hospital, Pauwelsstrasse 30, D-52074 Aachen, Germany and 4Department of 
Anaesthesia and Division of Critical Care, Dalhousie University Halifax, Queen 
Elisabeth II Health Sciences Center, 10 West Victoria, 1276 South Park St., 
Halifax, NS, B3H 2Y9, Canada
References
1. Hess JR, Brohi K, Dutton RP, Hauser CJ, Holcomb JB, Kluger Y, Mackway-
Jones K, Parr MJ, Rizoli SB, Yukioka T, Hoyt DB, Bouillon B: The 
coagulopathy of trauma: a review of mechanisms.  J Trauma 2008, 
65:748-754.
2. Mittermayr M, Streif W, Haas T, Fries D, Velik-Salchner C, Klingler A, 
Innerhofer P: Hemostatic changes after crystalloid or colloid fluid 
administration during major orthopedic surgery: the role of fibrinogen 
administration.  Anesth Analg 2007, 105:905-917.
3. Fenger-Eriksen C, Anker-Møller E, Heslop J, Ingerslev J, Sørensen B: 
Thrombelastographic whole blood clot formation after ex vivo 
addition of plasma substitutes: improvements of the induced 
coagulopathy with fibrinogen concentrate.  Br J Anaesth 2005, 
94:324-329.
4. Hiippala ST, Myllylä GJ, Vahtera EM: Hemostatic factors and replacement 
of major blood loss with plasma-poor red cell concentrates.  Anesth 
Analg 1995, 81:360-365.
5. Spahn DR, Cerny V, Coats TJ, Duranteau J, Fernández-Mondéjar E, Gordini 
G, Stahel PF, Hunt BJ, Komadina R, Neugebauer E, Ozier Y, Riddez L, 
Schultz A, Vincent JL, Rossaint R, Task Force for Advanced Bleeding Care in 
Trauma: Management of bleeding following major trauma: a European 
guideline.  Crit Care 2007, 11:R17.
6. O'Shaughnessy DF, Atterbury C, Bolton Maggs P, Murphy M, Thomas D, 
Yates S, Williamson LM, British Committee for Standards in Haematology, 
Blood Transfusion Task Force: Guidelines for the use of fresh-frozen 
plasma, cryoprecipitate and cryosupernatant.  Br J Haematol 2004, 
126:11-28.
7. Callum JL, Karkouti K, Lin Y: Cryoprecipitate: the current state of 
knowledge.  Transfus Med Rev 2009, 23:177-188.
8. Fries D, Krismer A, Klingler A, Streif W, Klima G, Wenzel V, Haas T, 
Innerhofer P: Effect of fibrinogen on reversal of dilutional 
coagulopathy: a porcine model.  Br J Anaesth 2005, 95:172-177.
9. Fries D, Innerhofer P, Reif C, Streif W, Klingler A, Schobersberger W, Velik-
Salchner C, Friesenecker B: The effect of fibrinogen substitution on 
reversal of dilutional coagulopathy: an in vitro model.  Anesth Analg 
2006, 102:347-351.
10. Haas T, Fries D, Velik-Salchner C, Reif C, Klingler A, Innerhofer P: The in 
vitro effects of fibrinogen concentrate, factor XIII and fresh frozen 
plasma on impaired clot formation after 60% dilution.  Anesth Analg 
2008, 106:1360-1365.
11. Bolliger D, Szlam F, Molinaro RJ, Rahe-Meyer N, Levy JH, Tanaka KA: 
Finding the optimal concentration range for fibrinogen replacement 
after severe haemodilution: an in vitro model.  Br J Anaesth 2009, 
102:793-799.
12. Ruggeri ZM: The role of von Willebrand factor and fibrinogen in the 
initiation of platelet adhesion to thrombogenic surfaces.  Thromb 
Haemost 1995, 74:460-463.
13. Ruggeri ZM: Mechanisms initiating platelet thrombus formation.  
Thromb Haemost 1997, 78:611-616.
14. Guide for the care and use of laboratory animals.  In Institute of 
Laboratory Animal Resources, Commission on Life Sciences, National 
Research Council 7th edition. Washington DC: National Academy Press; 
1996. 
15. Bush JA, Jesen WN, Cartwright GE, Wintrobe MM: Blood volume studies 
in normal and anemic swine.  Am J Physiol 1955, 181:9-14.
16. Moore EE, Cogbill TH, Jurkovich GJ, Shackford SR, Malangoni MA, 
Champion HR: Organ injury scaling: spleen and liver (1994 revision).  J 
Trauma 1995, 38:323-324.
17. Grottke O, Braunschweig T, Philippen B, Gatzweiler KH, Gronloh N, Staat 
M, Rossaint R, Tolba R: A new model for blunt liver injuries in the swine.  
Eur Surg Res 2010, 44:65-73.
18. Hiippala ST: Dextran and hydroxyethyl starch interfere with fibrinogen 
assays.  Blood Coagul Fibrinolysis 1995, 6:743-746.
19. Lang T, Toller W, Gütl M, Mahla E, Metzler H, Rehak P, März W, Halwachs-
Baumann G: Different effects of abciximab and cytochalasin D on clot 
strength in thrombelastography.  J Thromb Haemost 2004, 2:147-153.
20. Velik-Salchner C, Schnürer C, Fries D, Müssigang PR, Moser PL, Streif W, 
Kolbitsch C, Lorenz IH: Normal values for thrombelastography (ROTEM) 
Received: 24 January 2010 Revised: 9 March 2010 
Accepted: 14 April 2010 Published: 14 April 2010
This article is available from: http://ccforum.com/content/14/2/R62© 2010 Grottke et l.; licensee BioMed Central Ltd. is an pen ccess a ticl  distributed under he terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Critical Care 2010, 14:R62
Grottke et al. Critical Care 2010, 14:R62
http://ccforum.com/content/14/2/R62
Page 9 of 9and selected coagulation parameters in porcine blood.  Thromb Res 
2006, 117:597-602.
21. Wagner CL, Mascelli MA, Neblock DS, Weisman HF, Coller BS, Jordan RE: 
Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding 
to human platelets.  Blood 1996, 88:907-914.
22. Velik-Salchner C, Haas T, Innerhofer P, Streif W, Nussbaumer W, Klingler A, 
Klima G, Martinowitz U, Fries D: The effect of fibrinogen concentrate on 
thrombocytopenia.  J Thromb Haemost 2007, 5:1019-1025.
23. Lang T, Johanning K, Metzler H, Piepenbrock S, Solomon C, Rahe-Meyer N, 
Tanaka KA: The effects of fibrinogen levels on thromboelastometric 
variables in the presence of thrombocytopenia.  Anesth Analg 2009, 
108:751-758.
24. Nielsen VG, Gurley WQ Jr, Burch TM: The impact of factor XIII on 
coagulation kinetics and clot strength determined by 
thrombelastography.  Anesth Analg 2004, 99:120-123.
25. Schroeder V, Chatterjee T, Kohler HP: Influence of blood coagulation 
factor XIII and FXIII Val34Leu on plasma clot formation measured by 
thrombelastography.  Thromb Res 2001, 104:467-474.
26. Nielsen VG, Cohen BM, Cohen E: Effects of coagulation factor deficiency 
on plasma coagulation kinetics determined via thrombelastography: 
critical roles of fibrinogen and factors II, VII, X and XII.  Acta Anaesthesiol 
Scand 2005, 49:222-231.
27. Negrier C, Dargaud Y, Bordet JC: Basic aspects of bypassing agents.  
Haemophilia 2006, 12:48-52.
28. Kheirabadi BS, Crissey JM, Deguzman R, Holcomb JB: In vivo bleeding 
time and in vitro thrombelastography measurements are better 
indicators of dilutional hypothermic coagulopathy than prothrombin 
time.  J Trauma 2007, 62:1352-1359.
29. Society of Thoracic Surgeons Blood Conservation Guideline Task Force, 
Ferraris VA, Ferraris SP, Saha SP, Hessel EA, Haan CK, Royston BD, Bridges 
CR, Higgins RS, Despotis G, Brown JR, Society of Cardiovascular 
Anesthesiologists Special Task Force on Blood Transfusion, Spiess BD, 
Shore-Lesserson L, Stafford-Smith M, Mazer CD, Bennett-Guerrero E, Hill 
SE, Body S: Perioperative blood transfusion and blood conservation in 
cardiac surgery: the Society of Thoracic Surgeons and The Society of 
Cardiovascular Anesthesiologists clinical practice guideline.  Ann 
Thorac Surg 2007, 83:S27-S86.
30. Schols SE, Feijge MA, Lancé MD, Hamulyák K, ten Cate H, Heemskerk JW, 
van Pampus EC: Effects of plasma dilution on tissue-factor-induced 
thrombin generation and thromboelastography: partly compensating 
role of platelets.  Transfusion 2008, 48:2384-2394.
31. Jesty J, Beltrami E: Positive feedbacks of coagulation: their role in 
threshold regulation.  Arterioscler Thromb Vasc Biol 2005, 25:2463-2469.
32. Schols SE, Meijden PE van der, van Oerle R, Curvers J, Heemskerk JW, van 
Pampus EC: Increased thrombin generation and fibrinogen level after 
therapeutic plasma transfusion: relation to bleeding.  Thromb Haemost 
2008, 99:64-70.
33. Charbit B, Mandelbrot L, Samain E, Baron G, Haddaoui B, Keita H, Sibony O, 
Mahieu-Caputo D, Hurtaud-Roux MF, Huisse MG, Denninger MH, de Prost 
D, PPH Study Group: The decrease of fibrinogen is an early predictor of 
the severity of postpartum hemorrhage.  J Thromb Haemost 2007, 
5:266-273.
34. Karlsson M, Ternström L, Hyllner M, Baghaei F, Flinck A, Skrtic S, Jeppsson 
A: Prophylactic fibrinogen infusion reduces bleeding after coronary 
artery bypass surgery. A prospective randomised pilot study.  Thromb 
Haemost 2009, 102:137-144.
35. Rahe-Meyer N, Pichlmaier M, Haverich A, Solomon C, Winterhalter M, 
Piepenbrock S, Tanaka KA: Bleeding management with fibrinogen 
concentrate targeting a high-normal plasma fibrinogen level: a pilot 
study.  Br J Anaesth 2009, 102:785-792.
36. Fenger-Eriksen C, Jensen TM, Kristensen BS, Jensen KM, Tønnesen E, 
Ingerslev J, Sørensen B: Fibrinogen substitution improves whole blood 
clot firmness after dilution with hydroxyethyl starch in bleeding 
patients undergoing radical cystectomy: a randomized, placebo-
controlled clinical trial.  J Thromb Haemost 2009, 7:795-802.
37. Tatli E, Ozcelik F, Aktoz M: Plasma fibrinogen level may predict critical 
coronary artery stenosis in young adults with myocardial infarction.  
Cardiol J 2009, 16:317-320.
38. Dickneite G, Pragst I, Joch C, Bergman GE: Animal model and clinical 
evidence indicating low thrombogenic potential of fibrinogen 
concentrate (Haemocomplettan P).  Blood Coagul Fibrinolysis 2009 in 
press.
39. Dart AB, Mutter TC, Ruth CA, Taback SP: Hydroxyethyl starch (HES) versus 
other fluid therapies: effects on kidney function.  Cochrane Database 
Syst Rev 2010:CCD007594.
doi: 10.1186/cc8960
Cite this article as: Grottke et al., Effects of different fibrinogen concentra-
tions on blood losss and coagulation parameters in a pig model of coagul-
opathy with blunt liver injury Critical Care 2010, 14:R62
